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Background: Type 2 diabetes mellitus (T2DM) is a progressive disease resulting from increasing insulin resistance
and reduced pancreatic β-cell insulin secretion. Ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1)
inhibits insulin signalling and may contribute to the pathogenesis of T2DM. Others have found elevated ENPP1
levels in muscle, fat, and skin tissues from insulin resistant individuals, but similar data on liver ENPP1 is lacking.
The purpose of this study was to compare expression and protein concentrations of ENPP1 in liver between
patients with and without T2DM.
Methods: Roux-en-Y gastric bypass surgery (RYGB) results in remission of insulin resistance and T2DM thus
presenting an opportunity to examine some critical aspects of these conditions. We measured liver ENPP1 gene
and protein expression in individuals with or without T2DM at RYGB and on average 17 (±5.6) months later.
Results: We found liver ENPP1 protein abundance was lower in individuals with T2DM than in those with normal
glucose tolerance, and increased after RYGB surgery in those individuals who had remission of T2DM. ENPP1
positively correlated with insulin sensitivity at the liver (as measured by HOMA-IR), which is contrary to what others
have reported in other insulin target tissues.
Conclusions: Liver ENPP1 expression in T2DM is the reverse of that expected based on expression in other tissues
and is likely due to the unique role the liver has in insulin clearance. The work presented here adds another dimension
to the role of ENPP1, and supports the hypothesis that ENPP1 may act as a natural modulator of insulin signalling in
the liver.Background
Type 2 diabetes mellitus (T2DM) is a multifactorial disease
that results from increasing insulin resistance and relative
loss of pancreatic β-cell function. It has reached epidemic
proportions world-wide, with incidence predicted to
increase from ~285 million in 2010 to ~552 million by
the year 2030 [1,2]. At first used as therapy for morbid
obesity, bariatric surgery can also improve T2DM and
associated co-morbidities [3-5]. Although there is no clear
consensus on the mechanisms that cause remission of
diabetes, one common aspect among the varied bariatric
surgeries is the improvement in insulin sensitivity [6,7].* Correspondence: mark.hayes@anu.edu.au
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unless otherwise stated.Several molecules inhibit insulin signaling through the
insulin receptor (INSR) and may contribute to pathogenesis
of insulin resistance [8]. One of these is ectonucleotide
pyrophosphatase/phosphodiesterase 1 (ENNP1) which
interferes with insulin binding to the INSR α-subunit
[9]. Studies have shown ENPP1 protein abundance is
increased in skeletal muscle, adipose tissue and skin
fibroblasts from insulin resistant individuals [10-13].
Overexpressing ENPP1 in animals led to weakened
insulin signaling and action [14,15], while selectively
suppressing the levels of ENPP1 in the liver of mice
improved insulin sensitivity [16]. Despite the role of
ENPP1 in insulin resistance, data on its role in human
liver insulin resistance is lacking.
Roux-en-Y gastric bypass surgery can induce acute
remission of diabetes before any substantial weight loss
occurs [17-21]. Insulin resistance –as measured by
HOMA-IR– decreases rapidly post RYGB surgery with
improvements in diabetes [18,21,22], while peripheralhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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hyperinsulinemic clamp– only improves with substantial
weight loss [18,19]. As HOMA-IR is used in the fasting
state, where normoglycaemia is regulated by liver glucose
output, it is more indicative of liver insulin resistance. This
suggests improvement of liver insulin resistance is central
to remission of T2DM after RYGB surgery and provides a
unique opportunity to examine the role of ENPP1 in these
conditions.
In this study, our primary aim was to examine ENPP1
levels in liver tissue taken at RYGB surgery and later
after remission of diabetes. We hypothesized that liver
ENPP1 levels would be higher in individuals with T2DM
and would decrease after remission of diabetes.
Methods
We examined ENPP1 protein and mRNA expression
using liver tissue taken from individuals who underwent
open RYGB surgery as described in detail by our group
elsewhere [23]. All patients having RYGB surgery for
weight loss at Wakefield Hospital from 2001 to 2011
were considered for data and tissue collection. Procedures
were conducted under ethical approval from the Central
Health and Disability Ethics Committee of the New
Zealand Ministry of Health (approval No. WGT/00/04/
030). Written informed consent was given by all individuals
that were included in the study and all clinical investi-
gations were conducted according to the principles
expressed in the Declaration of Helsinki. All surgeries
were performed by the same surgeon (Professor Stubbs).
During RYGB surgery various blood and tissue samples
were taken including a liver biopsy using a Tru-Cut®
Soft Tissue Biopsy Needle (Cardinal Health). A secondTable 1 Anthropometric and metabolic data of 55 obese indi
Variables NGT (n = 19) IGT (n = 9)
Age 44 ± 8 47 ± 10
BMI (kg/m2) 46 ± 6 49 ± 4
HbA1c (%) 5.5 ± 0.4 5.6 ± 0.5
HOMA-IR 3.7 ± 3.6 6.1 ± 3.1
Fasting insulin (pmol/L) 109 ± 96 164 ± 80
Fasting glucose (mmol/L) 5.1 ± 0.6 5.7 ± 0.57
Gender
Female (%) 16 (84) 6 (66)
Male 3 3
Diabetes
Previously unrecognized (%) - -
Diet Controlled (%) - -
Oral hypoglycaemics (%) - -
Insulin taking (%) - -
rsNGT and rsT2DM groups represent the 16 individuals from the NGT and T2DM gr
significantly different; *p < 0.001, †p < 0.05 (ANOVA). Values are presented as meanliver biopsy was taken from most individuals who returned
for further unrelated surgery.
Fifty five individuals, from a tissue bank of 448, were
included in this study based on presence or absence of
diabetes and availability of cryogenically stored liver tissue.
The study group included those who had: normal glucose
tolerance (NGT group: n = 19), impaired glucose tolerance
(IGT group: n = 9), and type 2 diabetes (T2DM group:
n = 27) (Table 1). Sixteen individuals of the 55 had repeat
liver biopsy taken during unrelated procedures on average
17 (±5.6) months later and after significant weight loss. Of
the follow up surgeries, 14 were incisional hernia repairs,
while two were ring removal procedures. For comparisons
at RYGB, the groups are labelled NGT, IGT, T2DM, and
include the 16 patients who had repeat surgeries. Of the 16
repeat surgery individuals, 8 had diabetes which was in
remission by the time of second liver biopsy and 8 had nor-
mal glucose tolerance and were insulin sensitive at RYGB
surgery (Table 2). Duration of diabetes prior to its remission
in individuals who had a repeat liver biopsy is as follows:
diabetes was previously unrecognised in 3 patients, recently
diagnosed (<1 year) in 3, and had a duration of 5 and 9 years
in two others. These individuals were further classified into
four repeat operation groups as follows: individuals with
diabetes at RYGB surgery (rsT2DM-RYGB), individuals
with remission of diabetes at operation 2 (rsT2DM-OP2),
individuals with normal glucose tolerance at RYGB surgery
(rsNGT-RYGB), and individuals with normal glucose toler-
ance at operation two (rsNGT-OP2).
Data collection and T2DM diagnosis
Clinical data on all patients was collected prior RYGB
surgery and included: weight, height, body mass index,viduals at RYGB surgery
T2DM (n = 27) rsNGT (n = 8) rsT2DM (n = 8)
54 ± 7* 43 ± 9 50 ± 7
49 ± 10 44 ± 5 49 ± 10
7.6 ± 1.1* 5.4 ± 0.2 7.1 ± 1
10.8 ± 8.6* 2.5 ± 0.5 10.3 ± 6.2
196 ± 115† 80 ± 16 219 ± 127
8.1 ± 2.3* 4.9 ± 0.4 7.4 ± 1.9
15 (55) 6 (75) 5 (63)
12 2 3
7 (27) - 3 (37.5)
2 (8) - 1 (12.5)
14 (50) - 4 (50)
4 (15) - 0
oup respectively who had repeat liver biopsy. NGT vs T2DM data are
± SD.
Table 2 Metabolic status of individuals at RYGB and
operation 2
Variables rsNGT group (n = 8) rsT2DM group (n = 8)
RYGB OP2 RYGB OP2
BMI (kg/m2) 44 ± 5 28 ± 4* 49 ± 10 30 ± 5*
HbA1c (%) 5.4 ± 0.2 5.0 ± 0.7 7.1 ± 1 5.5 ± 0.2
†
HOMA-IR 2.5 ± 0.45 0.78 ± 0.34† 10.3 ± 6.2 1.4 ± 0.8*
FPI (pmol/L) 80 ± 16 27 ± 13* 219 ± 127 48 ± 23†
FPG (mmol/L) 4.9 ± 0.4 4.7 ± 0.4 7.4 ± 1.9 4.7 ± 0.6†
RYGB vs OP2 data are significantly different *p < 0.001, †p < 0.05 (Paired t-test).
Values are presented as mean ± SD.
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and fasting plasma insulin. Diagnosis of T2DM was
established by either 1) prior documentation of diagnosis
and/or receipt of treatment for T2DM or 2) diagnosis
based of an oral glucose tolerance test (OGTT) routinely
performed in all patients without a known history of
diabetes (plasma glucose > 11.1 mmol/l at 2 hours).
Impaired glucose tolerance was also diagnosed using
the OGTT (plasma glucose > 7.8 and < 11.0 mmol/l at
2 hours). Individuals with T2DM were further classified
as: previously unrecognized, diet controlled, needing
oral hypoglycaemic drugs or insulin taking. For those
individuals who had a second liver biopsy, weight, body
mass index, HbA1c, fasting plasma glucose and fasting
plasma insulin were measured within 2 months of the
second surgery. Remission of T2DM was defined accord-
ing to recommendations of Buse et al. (HbA1c% <6.5%,
fasting plasma glucose was <5.6 mmol/l and no continu-
ing treatment one year after surgery) [24].
Biochemical testing
All patients undertook a 12 hour fast prior to blood
collection for biochemical tests. Fasting was either self-
administered or administered during the hospital stay.
Clinical biochemistry testing was conducted by Aotea
Pathology (Wellington, New Zealand) while testing for
insulin was undertaken at Canterbury Health Labora-
tories (Christchurch, New Zealand).
Estimation of insulin resistance
Homeostasis model assessment (HOMA) was used to
estimate insulin resistance [25]. HOMA-IR less than 2.5
has been shown to be representative of a metabolically
normal, insulin sensitive population [26].
Liver RNA extraction
Total RNA was extracted using TRIzol® (Life Technologies)
as per the manufacturer’s instructions. Briefly, 2-3 mg of
frozen liver tissue was pulverized under liquid nitrogen and
800 μl of TRIzol® was added to the resultant powder which
was then homogenised with an Omni Tissue Homogenizer(Omni International). 200 μl of chloroform was added to
separate the mixture into a red phenol-chloroform phase,
an interphase and an RNA containing colourless upper
aqueous phase. The aqueous phase was collected and total
RNA was precipitated with isopropyl alcohol and Glyco-
Blue (50 μg/mL) (Life Technologies). The resultant RNA
pellet was washed with 75% ethanol, air dried and
re-suspended in 20 μl DEPC-treated water. RNA was stored
at −80°C prior to quality control and use in first strand
cDNA synthesis. Quality and quantity of RNA was analyzed
on the 2100 Agilent Bioanalyzer, using the Agilent RNA 600
Nano kit and BioSizing software (Agilent Technologies).
cDNA synthesis and RT-qPCR
Total RNA was reverse transcribed using the Super-
Script Vilo cDNA synthesis kit (Life Technologies)
according to the manufacturer instructions. 1 μg of RNA
was added to a 20 μl reaction mixture and the resulting
cDNA was diluted 1:10 and stored at −20°C prior to
use in RT-qPCR reactions. EXPRESS qPCR SuperMix
(Life Technologies) and TaqMan Gene Expression Assays
(ENPP1/PC-1 Hs 01054040_m1- Applied Biosystems)
were used for all RT-qPCR reactions which were con-
ducted on an ABI 7300 Real-Time PCR System (Applied
Biosystems). Each sample was run in triplicate and each
time a threshold cycle (Ct) was obtained using the 7300
Sequence Detection Software 1.3.1. The average of all
three replicates for a particular sample was calculated
and used in subsequent data analysis. Changes in gene
expression were expressed as relative amount normalised
to a reference gene and as fold change, both of which were
calculated using the RQ method (2-ΔΔCt). Eukaryotic 18S
rRNA (4319413E, Applied Biosystems) was used as the
reference gene.
Liver protein extraction
Protein for three of the individuals included in the study
was not available for the RYBG time point. Protein was
extracted by pulverizing 3-4 mg of frozen liver under
liquid nitrogen. The resultant powder was incubated with
buffer containing Complete Protease Inhibitor Cocktail
(Roche), 30 mM TrisCl, 7 M urea, 2 M thiourea and 4%
(w/v) CHAPS) for 45 minutes on ice, with vigorous
vortexing every 15 minutes. The mixture was centrifuged at
14000 g for 10 minutes to remove any insoluble material.
The supernatant was aliquoted for storage at −80°C. Protein
was quantified using Bradford reagent (Bio Rad) on a
Bio-Rad Benchmark microplate reader [27].
E-PAGE electrophoresis and western blotting
An E-PAGE 48 well protein electrophoresis system was
used to resolve protein samples on pre-cast E-PAGE 48
well 8% gels (20-300 kDa separation range) (Life Technolo-
gies) under denaturing conditions. Two separate gels were
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and the second containing 13 sets of samples from the
patients who had repeat operations. Results for the RYGB
comparison from the second gel were combined with the
first for analysis purposes. SeeBlue Plus2 Pre-stained Stand-
ard (Life technologies) and MagicMark XP Western Protein
Standard (Life technologies) were used as molecular
weights to assess protein migration during electrophoresis
and western blotting respectively. Protein was transferred
onto Hybond-P PVDF membrane (Amersham) and
blocked with 5% skim milk powder in TBS-Tween at 4°C
overnight. Membranes were probed for 2 h at room
temperature with monoclonal ENPP1/PC-1 (1:500, Clone
F-8, Santa Cruz) [28], or monoclonal anti-actin (1:10000,
Clone C4, Millipore). Blots were then incubated with alka-
line phosphatase-conjugated anti mouse antibody (Life
Technologies) for 0.5 h. The chemiluminescent signal was
developed using CDP-Star chemiluminesent substrate
(Life Technologies) and captured on x-ray film (Kodak).
The protein bands on the x-ray film were digitized by the
Chemidoc XRS system (Bio Rad) and then analyzed using
Quantity One software (Bio Rad). Bands were quantified
and expressed as volume; the sum of the intensities of the
pixels within a defined volume boundary × pixel area
(intensity units ×mm2). Local background subtraction was
used to facilitate background correction. Protein relative
abundance was calculated by normalizing the volume of
the ENPP1 band to the volume of the Actin band.
Statistical analysis
Statistical analysis was performed on 2-ΔCt RT-qPCR data
between each study group. Consequently gene expression
data was expressed as both 2-ΔCt in graphical form,
whereas the fold change for significant differences was
reported in text. Statistical analysis of protein abundance
was performed on the value generated from normalisation
of band intensity to the loading control.
Normal distribution of all groups to be compared was
tested with Kolmogorov-Smirnov test. Non-normally dis-
tributed data was log transformed to comply with paramet-
ric test assumptions. Pre-post comparisons were carried out
using a paired t-test. ANOVA with Bonferroni correction
was used to test significance between groups. The Pearson
product–moment correlation coefficient was used to test the
strength and significance of association between variables.
An alpha level of 0.05 was set as the significance threshold.
All analysis was performed using Minitab 15. Graphical
visualization was performed using GraphPad Prism 5.
Results
Liver ENPP1 levels at RYGB surgery
We measured levels of ENPP1 mRNA expression and
protein abundance in individuals with and without
T2DM and again after resolution of insulin resistance andremission of T2DM. Table 1 summarizes the relevant an-
thropometric data and metabolic characteristics for the
study groups around the time of RYGB surgery. All individ-
uals were morbidly obese before surgery (BMI > 40 kg/m2)
and there were no statistically significant differences in BMI
between any of the groups. The T2DM group was signifi-
cantly older than the NGT group, likely owing to the
chronic and progressive nature of the disease. Mean fasting
plasma glucose and HbA1c levels were normal in the NGT
group, and slightly raised in the IGT group. However there
were no statistically significant differences between the
NGT and IGT group in any of the parameters measured at
RYGB surgery. The T2DM group had significantly higher
(p < 0.001, ANOVA) HbA1c and fasting glucose levels than
the NGT group. Although insulin resistance was present in
varying severity in all groups, the T2DM group were the
most insulin resistant as they had the highest mean fasting
plasma insulin concentration and HOMA-IR values, which
was only significantly different between the T2DM and the
NGTgroup (p < 0.001, ANOVA).
We found that liver ENPP1 gene expression was −1.5
(95% CI −6.2 to 2.8) fold lower in the T2DM group
when compared to the NGT group (Figure 1A, p = 0.04,
ANOVA), while there was no difference in ENPP1
mRNA expression between the NGT and IGT group.
Figure 1C displays the western blot for ENPP1 protein
abundance only for the 39 individuals who did not have
a second liver biopsy (See Additional file 1 - Uncropped
Western Blots, Figures 1 (ENPP1) & 3 (Actin) for un-
cropped original blots). To avoid gel bias, sample loading
was alternated based on disease state. The molecular
weight of ENPP1 in SDS-PAGE is 110–130 kd depending
on tissue type. Some proportion of ENPP1 reportedly exists
as dimer and the 220kd band visible in Figure 1C is most
likely the dimeric form of ENPP1 [29]. The liver ENPP1
protein abundance was −2 fold lower (95% CI, −3.6
to −1.3) in the T2DM group in comparison to the NGT
group (Figure 1B), which was also statistically significant
(p = 0.04, t-test). To control for the effect of treatment on
ENPP1 levels, we performed ANOVA analysis to test
whether different treatments for diabetes affected ENPP1
levels. There was no significant differences in ENPP1
mRNA (p = 0.221) or ENPP1 protein (0.362) between pre-
viously unrecognized, diet controlled, insulin taking, or
oral hypoglycemic taking individuals. Although ENPP1
protein abundance was lower in the IGT group, it did not
reach statistical significance. Retrospective power calcula-
tions show that while the sample sizes in the NGT and
T2DM are sufficient to reject the null hypothesis (α-level
0.05, power 0.83), the small sample size in the IGT group
is limiting and another 36 observations would be needed
to reach a statistically significant result.
To explore any relationship between liver ENPP1 protein
and insulin sensitivity, we calculated a Pearson product–
Figure 1 ENPP1 gene expression and protein abundance in liver tissue of morbidly obese individuals at RYGB surgery. (A) ENPP1 mRNA
expression presented as 2-ΔCt normalised to 18S. (B) ENPP1 protein abundance relative to Actin. Both ENPP1 mRNA and protein abundance was
significantly lower in the T2DM group in comparison to the NGT group. (C) ENPP1 western blot from liver of 39 individuals who did not have
a second liver biopsy. The remaining 13 samples were run on a different gel (Figure 3B) so as to facilitate easier comparison of ENPP1 protein
before and after remission of diabetes and insulin resistance. The data from the two gels was combined for analysis of samples at RYGB. Black
lines denote non-adjacent lanes. For uncropped blots see additional document 1. NGT; Normal glucose tolerance (n = 19), IGT; Impaired glucose
tolerance (n = 9), T2DM; Type 2 diabetes (n = 27). Data is presented as mean + SE.
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ENPP1 protein abundance negatively correlated with
HOMA-IR in the whole cohort (Figure 2), suggesting
a positive association between ENPP1 and insulin
sensitivity.Figure 2 ENPP1 relationship with liver insulin sensitivity.
Pearson product–moment correlation of liver ENPP1 protein relative
abundance (log) vs HOMA-IR (log) (n = 52).Liver ENPP1 levels before and after RYGB surgery
One of the novel characteristics of this study is the use
of liver tissue biopsied from the same individual before
and after significant weight loss and improvement in
insulin sensitivity and/or remission of type 2 diabetes.
Liver ENPP1 mRNA expression and protein abundance
was measured in individuals who had normal glucose
tolerance (rsNGT group) or T2DM (rsT2DM group) at
RYGB and at a second operation 17 months later. Table 2
lists the metabolic characteristic for the rsNGT and
rsT2DM groups at first and second liver biopsy. Out of
the 16 individuals who had a second liver biopsy, two
had incomplete follow up data. Both the rsNGT and
rsT2DM groups had significant decreases in BMI by the
second operation. There were no statistically significant
differences in BMI between the two groups at either
operation or in amount of weight lost, thus removing
weight loss as a potential confounding factor. The rsT2DM
group had a significant (p < 0.05, paired t-test) decrease in
mean fasting plasma glucose and HbA1c levels, represent-
ing remission of T2DM. Liver insulin sensitivity (as
measured by HOMA-IR) improved dramatically in both
the rsNGT and rsT2DM group. The rsT2DM group had
the greatest improvement in insulin sensitivity which
coincided with remission of diabetes.
Figure 3A shows the mean liver ENPP1 protein abun-
dance for all 13 individuals who had liver protein
extracted at RYGB surgery and on average 17 months
Figure 3 Liver ENPP1 protein abundance at RYGB surgery and at operation 2. (A) ENPP1 protein abundance had a significant increase in
the rsT2DM group after RYGB surgery. (B) Corresponding western blot for ENPP1 for individuals that had a second liver biopsy. Black lines denote
non-adjacent lanes. For uncropped blots see additional document 1. rsNGT ●: repeat surgery normal glucose tolerance (n = 6); rsT2DM ○: repeat
surgery type 2 diabetes (n = 7). Data is presented as mean + SE.
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Additional file 1 - Uncropped Western Blots - Figures 2
(ENPP1) and 4 (Actin) for original uncropped images).
There were six pairs of liver from the rsNGT group while
there were seven pairs of samples from the rsT2DM group.
Although the rsNGT group had no great change in liver
ENPP1 protein levels after RYGB surgery, the rsT2DM
group had a statistically significant (p = 0.01, paired t-test)
increase in ENPP1 protein abundance (Figure 3A). The in-
dividuals who had resolution of insulin resistance and re-
mission of T2DM following RYGB had a mean 2.7 (95% CI,
1.8 to 4.0) fold increase in liver ENPP1 protein abundance.
Thus, improvement in liver insulin sensitivity after RYGB
surgery as measured by HOMA-IR was concomitant with
increasing levels of ENPP1 protein at the liver in humans.
Neither group had significant changes in liver ENPP1 gene
expression after RYGB surgery (data not shown), suggest-
ing that post translational regulation is more important in
the regulation of ENPP1 protein level with change in insu-
lin resistance and remission of diabetes.Discussion
ENPP1 may contribute to insulin resistance through its
inhibitory action on insulin signalling. Although others
have studied ENPP1 in various human tissues (skin,
muscle, and adipose tissue) [10-12], relatively little is
known about ENPP1 levels in human liver. Improve-
ment in liver insulin resistance is associated with early
improvements in glycaemic control post RYGB surgery.
This occurs before significant weight loss and associated
improvements in insulin resistance in fat and muscle,suggesting that the liver may be a critical component of the
metabolic changes seen post-surgery [18-22]. For this rea-
son we used liver tissue taken at RYGB surgery to examine
the role of ENPP1 in liver insulin resistance. RYGB surgery
improved liver insulin sensitivity –as measured by HOMA-
IR– regardless of diabetes status, while remission of T2DM
was associated with normalisation of fasting plasma insulin
concentrations and HOMA-IR values.
From the current literature on ENPP1 we expected
that its levels would be high in individuals with T2DM
and decrease after remission of the disease. Surprisingly,
liver ENPP1 mRNA and protein was lower in individuals
with T2DM in comparison to individuals with normal
glucose tolerance (Figure 1A and B) at RYGB. In the
subset of individuals who had a second liver biopsy, only
those that had remission of diabetes and improvement
in insulin sensitivity had an increase in liver ENPP1
protein abundance (Figure 3A).
However, ENPP1 mRNA expression did not change
significantly after remission of diabetes, even though
individuals with T2DM had lower expression than those
with normal glucose tolerance at RYGB surgery. This is
likely caused by post transcriptional processing as insulin
has been shown to affect liver ENPP1 protein abundance
without changing its gene expression [30], which is in
agreement with data presented here. Individuals with
impaired glucose tolerance also tended to have decreased
liver ENPP1 protein, and the pattern of liver ENPP1 pro-
tein abundance in the IGT and T2DM groups is likely
caused by high circulating levels of insulin as both groups
had moderate to severe insulin resistance respectively. In
this study there was a significant association between
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liver insulin sensitivity (Figure 2).
Although our data do not agree with studies that have
associated increased ENPP1 content in muscle and adipose
tissue with insulin resistance [10-13], there is conflicting
evidence as to ENPP1’s role in the pathology of diabetes.
Pender et al. have shown no change in muscle ENPP1
content in morbidly obese humans after bariatric surgery
where there had been a measured increase in insulin sensi-
tivity [31]. In a Zucker diabetic fatty rat model of T2DM
there was no difference in muscle and liver ENPP1 content
in comparison to control animals [29]. Even though some
experimentally produced T2DM animal models had
increased ENPP1 content [32], others did not [33,34].
We suspect that the conflicting evidence reported in
the literature and our own data presented here is due to
the varied roles muscle, fat, and liver tissues have in
regulating insulin action. The liver has a crucial role in
regulating the systemic insulin concentration by hepatic
insulin clearance [35]. It is the first organ to receive
large amounts of insulin released from the pancreas
during the first phase response (1000–5000 pmol/l) and
removes ~50% of it from the blood stream [36,37]. Con-
sidering the liver extracts and recycles supraphysiological
levels of insulin during first phase insulin secretion,
preventing overstimulation of metabolic pathways may
be necessary for normal glucose homeostasis. In line
with this theory, individuals with insulin receptor or
IRS-1 mutations resulting in defunct insulin signalling
have low ENPP1 activity and content [38]. Menzaghi et al.
have suggested ENPP1 may act as a natural desensitiser of
insulin signalling because of insulin’s ability to stimulate
ENPP1 post-translational processing and recruitment to
the plasma cell membrane [30]. Our data presented here
is in accordance with this hypothesis.
However, there are some limitations to the data pre-
sented here. Stefanovic et al. reported previously that
metformin treatment can influence ENPP1 activity in
lymphocytes from individuals with diabetes [39], while
half of the individuals with diabetes in our study were
on oral hypoglycemics (metformin). Nonetheless, we
found no significant differences in ENPP1 mRNA or
protein levels between different treatments for diabetes,
including metformin, which is in agreement with that of
Ludovico et al. who have also shown that metformin
does not affect ENPP1 mRNA levels in lymphocytes [40].
Repeat human liver samples are exceedingly hard to
obtain and consequently there has been little published on
the changes in liver gene and protein expression associ-
ated with the remission of diabetes post-RYGB. The small
sample size in the IGT group limits interpretation of this
data, but our study has sufficient power when comparing
the NGT and T2DM groups to suggest that ENPP1 may
not contribute to insulin resistance at the liver but is anormal biological regulator of insulin action in an organ
which is exposed to very high levels of insulin.
Conclusions
In this study, we have shown a reverse ENPP1 pattern to
that previously described in muscle and adipose tissue of
insulin resistant individuals. Liver ENPP1 protein abun-
dance was lower in the liver of individuals with T2DM in
comparison to individuals with normal glucose tolerance
and increased after remission of T2DM. We believe this is
likely due to the role of the liver in insulin processing, and
our data is in agreement with the previously supposed
hypothesis that ENPP1 is a natural regulator of insulin
signalling strength. The decreased levels of liver ENPP1
during hyperglycaemic conditions such as diabetes may be
a compensatory response to increase insulin signalling and
regain control of glucose homeostasis. Although our work
does not discount the possibility that ENPP1 contributes to
insulin resistance, it does add another dimension that will
have to be considered in future work exploring the influ-
ence ENPP1 has on liver insulin signalling.
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